Top news of the week: 22.09.2020.

#moversandshakers #Biotech #academictwitter #Academia #synbio #biotechnology #academicchatter #biospace #lifesciences #pharmaceuticals

Career And Jobs

On Sep 21, 2020
@BiotechWorld shared
Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field  https://t.co/yOi58cMWRW https://t.co/ZR4CAmERuk
Open

Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field

Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field

Roche has bought Inflazome for €380 million ($451 million) upfront to gain control of treatments for inflammatory diseases. The deal gives Roche full rights to a pipeline of oral NLRP3 ...

On Sep 17, 2020
@SynBioBeta shared
Should you go into #Biotech or #Academia? It’s 2020 and the ideological divide between the Biotech industry and academic research is closing fast. https://t.co/2IcdvuPbE9 @BioeconomyXYZ #academictwitter #academicchatter #synbio
Open

Should you go into Biotech or Academia?

Should you go into Biotech or Academia?

It’s 2020 and the ideological divide between the Biotech industry and academic research is closing fast.

On Sep 18, 2020
@FiercePharma shared
Special Report: Biopharma nurtures the next generation of immuno-oncology targets https://t.co/277FpCUFsX
Open

Special Report: Biopharma nurtures the next generation of immuno-oncology targets

Special Report: Biopharma nurtures the next generation of immuno-oncology targets

The first wave of immuno-oncology drugs was targeted at immune checkpoints and produced blockbusters like Merck’s PD-1 inhibitor Keytruda. The next wave includes second-generation ...

On Sep 19, 2020
@SynBioBeta shared
[email protected] is looking for a Research Scientist. The successful candidate will be a pivotal member of the team, supporting in the assembly of colour pathways from strain engineering through to dye characterisation on the fabric. https://t.co/1nwUUt5bpl
Open

Research Scientist: Colorifix – Norwich Research Park, Norwich

Research Scientist: Colorifix – Norwich Research Park, Norwich

Colorifix is a biotechnology company that aims to bring a novel, sustainable and environmentally-friendly process to the textile dyeing industry by eliminating the use of hazardous ...

On Sep 17, 2020
@SynBioBeta shared
Debut Biotechnology awarded $1 million​ to leverage cell-free continuous biomanufacturing in aerospace applications https://t.co/xaGTKyRTxv
Open

Debut Biotechnology Awarded $1M from Air Force Research Lab to Leverage Cell-Free Continuous Biomanufacturing in Aerospace Applications

Debut Biotechnology Awarded $1M from Air Force Research Lab to Leverage Cell-Free Continuous Biomanufacturing in Aerospace Applications

Debut Bio’s biosynthesis platform provides a scalable biomanufacturing approach while eliminating the need for traditional precious metal catalysts and toxic reagents SAN DIEGO ...

On Sep 18, 2020
@biospace shared
BioSpace Movers & Shakers, Sept. 18 #biospace #lifesciences #biotechnology #pharmaceuticals #moversandshakers https://t.co/GNWWIDs1G4
Open

BioSpace Movers & Shakers, Sept. 18

BioSpace Movers & Shakers, Sept. 18

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

On Sep 21, 2020
@ScienceMagazine shared
After a long career in research, this scientist found an unexpected way to help people during the #COVID19 pandemic—by working as a letter carrier. Read their story in this week's #SciMagWorkingLife. https://t.co/ZlejukuwXF
Open

I’m a scientist making a difference during the pandemic—as a letter carrier

I’m a scientist making a difference during the pandemic—as a letter carrier

After a long career in research, this scientist found an unexpected way to help people

On Sep 16, 2020
@JohnCendpts shared
Interested in next-gen gene editing work? Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell By @AmberTongPW https://t.co/k7o4zX30op
Open

Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell

Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell

When a researchers talk about gene editing, they're usually thinking about several steps. First you need to zero in on the defective gene; then, depending on the need, you’d want to knock ...